Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
Therapeutic Advances in Medical Oncology|December 22, 2025
Current landscape of sequencing ADCs in metastatic breast cancerShannon McLaughlin, Lis V Ravani, Beverly Moy, et al.
NPJ Breast Cancer|March 12, 2025
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsiesYael Bar, Geoffrey Fell, Aylin Dedeoglu, et al.
NEJM Evidence|May 30, 2024
CDK4/6 Inhibitor Efficacy in <i>ESR1</i>-Mutant Metastatic Breast CancerMaxwell R Lloyd, Jamie O Brett, Ariel Carmeli, et al.
Oncogene|February 17, 2015
Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulationD Zhao, A H Besser, S A Wander, et al.
JCO Precision Oncology|February 17, 2022
Combined Targeted Therapy for <i>BRAF</i>-Mutant, Treatment-Related Acute Myeloid LeukemiaSeth A Wander, Robert P Hasserjian, Kwadwo Oduro, et al.
Breast Cancer Research and Treatment|March 20, 2016
Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapySeth A Wander, Dekuang Zhao, Alexandra H Besser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2025
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast CancerHope S Rugo, Virginia Kaklamani, Heather McArthur, et al.
Future Oncology (London, England)|April 13, 2025
ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, <i>ESR1</i>-mutated, metastatic breast cancerMatthew P Goetz, Seth A Wander, Thomas Bachelot, et al.
Breast Cancer Research and Treatment|February 23, 2013
PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapySeth A Wander, Dekuang Zhao, Alexandra H Besser, et al.
Breast Cancer Research and Treatment|May 5, 2026
Long-term outcomes in triple-negative breast cancer after a pathologic complete response: does the type of neoadjuvant therapy matter?Lis Victória Ravani, Seth A Wander, Marleen Kok, et al.
Pageof 9